{"id":53131,"date":"2026-01-07T20:47:56","date_gmt":"2026-01-07T12:47:56","guid":{"rendered":"https:\/\/flcube.com\/?p=53131"},"modified":"2026-01-07T20:47:57","modified_gmt":"2026-01-07T12:47:57","slug":"lilly-nears-1-billion-deal-for-ventyxs-ibd-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53131","title":{"rendered":"Lilly Nears $1 Billion Deal for Ventyx&#8217;s IBD Pipeline"},"content":{"rendered":"\n<p><strong>Eli Lilly (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>)<\/strong> is in advanced talks to acquire <strong>Ventyx Biosciences<\/strong> for more than <strong>USD\u202f1\u202fbillion<\/strong>, according to a Wall Street Journal report. The acquisition would bolster Lilly\u2019s pipeline with <strong>inflammatory bowel disease (IBD) treatments<\/strong> for Crohn\u2019s disease and ulcerative colitis, Parkinson\u2019s disease therapies, and a mid\u2011stage cardiovascular drug for obesity\u2011related conditions. Neither company has commented on the report.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Eli Lilly &amp; Co. (NYSE: LLY)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Ventyx Biosciences<\/td><\/tr><tr><td><strong>Deal Value<\/strong><\/td><td>&gt; USD\u202f1\u202fbillion<\/td><\/tr><tr><td><strong>Key Assets<\/strong><\/td><td>IBD drugs (Crohn\u2019s, ulcerative colitis), Parkinson\u2019s therapies, cardiovascular disease drug<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Mid\u2011stage (cardiovascular drug) to late\u2011stage (IBD)<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Advanced talks, no official comment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>Pipeline Diversification<\/strong>: The deal would add <strong>first\u2011in\u2011class IBD therapies<\/strong> to Lilly\u2019s portfolio, reducing reliance on its <strong>diabetes\/obesity franchise<\/strong> (Mounjaro, Zepbound) which generated <strong>65%<\/strong> of 2025 revenue.<\/p>\n\n\n\n<p><strong>Market Expansion<\/strong>: IBD affects <strong>8\u201110\u202fmillion<\/strong> patients globally with <strong>\u00a550\u202fbillion<\/strong> (US$7\u202fbillion) annual market; Parkinson\u2019s disease represents <strong>\u00a535\u202fbillion<\/strong> opportunity.<\/p>\n\n\n\n<p><strong>Obesity\u2011CV Link<\/strong>: Ventyx\u2019s cardiovascular drug targets <strong>obesity\u2011related atherosclerosis<\/strong>, complementing Lilly\u2019s <strong>tirzepatide<\/strong> cardioprotection strategy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>IBD Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global<\/strong>: <strong>$15\u201118\u202fbillion<\/strong> (2025), growing at <strong>8% CAGR<\/strong><\/li>\n\n\n\n<li><strong>China<\/strong>: <strong>\u00a55.2\u202fbillion<\/strong> (2025), underserved with <strong>high diagnosis gap<\/strong><\/li>\n\n\n\n<li><strong>Competition<\/strong>: <strong>AbbVie (Skyrizi, Rinvoq)<\/strong> and <strong>J&amp;J (Stelara)<\/strong> dominate; Ventyx\u2019s <strong>S1P modulator<\/strong> offers <strong>oral convenience<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Parkinson\u2019s Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global<\/strong>: <strong>$8.5\u202fbillion<\/strong> (2025)<\/li>\n\n\n\n<li><strong>Ventyx Asset<\/strong>: <strong>Alpha\u2011synuclein targeting antibody<\/strong> in Phase\u202fII, <strong>differentiated mechanism<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Cardiovascular Disease<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity\u2011Related CV Risk<\/strong>: <strong>30\u201140%<\/strong> of obese patients develop <strong>CAD\/stroke<\/strong><\/li>\n\n\n\n<li><strong>Ventyx Drug<\/strong>: <strong>PCSK9\u2011siRNA<\/strong> hybrid in Phase\u202fIIb, potential <strong>\u00a510\u202fbillion<\/strong> peak sales<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>IBD Franchise<\/th><th>Stage<\/th><th>MoM Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>AbbVie<\/strong><\/td><td>Skyrizi, Rinvoq<\/td><td>Marketed<\/td><td>+12%<\/td><\/tr><tr><td><strong>J&amp;J<\/strong><\/td><td>Stelara, Tremfya<\/td><td>Marketed<\/td><td>+8%<\/td><\/tr><tr><td><strong>Pfizer<\/strong><\/td><td>Etrasimod<\/td><td>Phase\u202fIII<\/td><td>N\/A<\/td><\/tr><tr><td><strong>Ventyx<\/strong><\/td><td><strong>VTX002 (S1P)<\/strong><\/td><td>Phase\u202fIII<\/td><td><strong>Acquisition target<\/strong><\/td><\/tr><tr><td><strong>Lilly (post\u2011deal)<\/strong><\/td><td>VTX002 + pipeline<\/td><td><strong>Phase\u202fIII<\/strong><\/td><td><strong>New entrant<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Gap<\/strong>: Lilly currently has <strong>no IBD assets<\/strong>; this acquisition would <strong>instantly establish<\/strong> a specialty franchise.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p><strong>For Lilly<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cash Use<\/strong>: Deploys <strong>$8\u202fbillion cash reserve<\/strong>; deal is <strong>accretive<\/strong> by 2028 based on Ventyx\u2019s pipeline value<\/li>\n\n\n\n<li><strong>Revenue Synergy<\/strong>: Cross\u2011selling opportunities via <strong>Lilly\u2019s 5,000\u2011person primary care sales force<\/strong><\/li>\n\n\n\n<li><strong>R&amp;D Leverage<\/strong>: Ventyx\u2019s <strong>San Diego R&amp;D hub<\/strong> complements Lilly\u2019s <strong>immunology research<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>For Ventyx<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Premium Valuation<\/strong>: <strong>$1\u202fbillion+<\/strong> represents <strong>120\u2011150% premium<\/strong> to last trading price<\/li>\n\n\n\n<li><strong>Validation<\/strong>: Confirms <strong>platform value<\/strong> after <strong>S1P modulator success<\/strong><\/li>\n\n\n\n<li><strong>Exit<\/strong>: Provides liquidity to <strong>VC investors<\/strong> (Pfizer Ventures, Abingworth)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-timeline\">Deal Structure &amp; Timeline<\/h2>\n\n\n\n<p><strong>Expected Closing<\/strong>: Q2\u202f2026, pending <strong>due diligence and board approvals<\/strong>.<\/p>\n\n\n\n<p><strong>Payment Structure<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>60% cash<\/strong>, <strong>40% stock<\/strong> (estimated) to preserve Lilly\u2019s balance sheet flexibility<\/li>\n\n\n\n<li><strong>Contingent Value Rights (CVRs)<\/strong>: Tied to <strong>VTX002 Phase\u202fIII success<\/strong> and <strong>Parkinson\u2019s asset advancement<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Integration<\/strong>: Ventyx to operate as <strong>Lilly Immunology Division<\/strong>, retaining <strong>80% of staff<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the transaction\u2019s completion, integration success, and Ventyx asset commercialization. Actual results may differ materially due to regulatory hurdles, clinical trial outcomes, and competitive responses in the IBD market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly (NYSE: LLY) is in advanced talks to acquire Ventyx Biosciences for more than&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[199,911,4533],"class_list":["post-53131","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-eli-lilly","tag-nyse-lly","tag-ventyx-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lilly Nears $1 Billion Deal for Ventyx&#039;s IBD Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53131\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lilly Nears $1 Billion Deal for Ventyx&#039;s IBD Pipeline\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53131\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T12:47:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T12:47:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53131#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53131\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lilly Nears $1 Billion Deal for Ventyx&#8217;s IBD Pipeline\",\"datePublished\":\"2026-01-07T12:47:56+00:00\",\"dateModified\":\"2026-01-07T12:47:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53131\"},\"wordCount\":493,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Ventyx Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53131#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53131\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53131\",\"name\":\"Lilly Nears $1 Billion Deal for Ventyx's IBD Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T12:47:56+00:00\",\"dateModified\":\"2026-01-07T12:47:57+00:00\",\"description\":\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53131#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53131\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53131#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly Nears $1 Billion Deal for Ventyx&#8217;s IBD Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lilly Nears $1 Billion Deal for Ventyx's IBD Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53131","og_locale":"en_US","og_type":"article","og_title":"Lilly Nears $1 Billion Deal for Ventyx's IBD Pipeline","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=53131","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T12:47:56+00:00","article_modified_time":"2026-01-07T12:47:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53131#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53131"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lilly Nears $1 Billion Deal for Ventyx&#8217;s IBD Pipeline","datePublished":"2026-01-07T12:47:56+00:00","dateModified":"2026-01-07T12:47:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53131"},"wordCount":493,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eli Lilly","NYSE: LLY","Ventyx Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53131#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53131","url":"https:\/\/flcube.com\/?p=53131","name":"Lilly Nears $1 Billion Deal for Ventyx's IBD Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T12:47:56+00:00","dateModified":"2026-01-07T12:47:57+00:00","description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53131#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53131"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53131#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lilly Nears $1 Billion Deal for Ventyx&#8217;s IBD Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53131"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53131\/revisions"}],"predecessor-version":[{"id":53227,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53131\/revisions\/53227"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}